|
Volumn 84, Issue 7, 2001, Pages 886-891
|
Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial
|
Author keywords
Hepatocellular carcinoma; HMG CoA reductase inhibitor; Pravastatin; Survival
|
Indexed keywords
FLUOROURACIL;
HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;
PRAVASTATIN;
ADULT;
ADVANCED CANCER;
AGED;
ARTICLE;
ARTIFICIAL EMBOLISM;
CANCER CHEMOTHERAPY;
CANCER SURVIVAL;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DEATH;
DISEASE COURSE;
DRUG EFFECT;
ECHOGRAPHY;
FEMALE;
HUMAN;
LIVER CELL CARCINOMA;
LIVER DYSFUNCTION;
MAJOR CLINICAL STUDY;
MALE;
PRIORITY JOURNAL;
RANDOMIZED CONTROLLED TRIAL;
SURVIVAL TIME;
TUMOR GROWTH;
ADULT;
AGED;
ALANINE TRANSAMINASE;
ALPHA-FETOPROTEINS;
ANTIMETABOLITES, ANTINEOPLASTIC;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
BILIRUBIN;
CARCINOMA, HEPATOCELLULAR;
DRUG ADMINISTRATION SCHEDULE;
EMBOLIZATION, THERAPEUTIC;
FEMALE;
FLUOROURACIL;
HUMANS;
HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;
LIVER NEOPLASMS;
MALE;
MIDDLE AGED;
PRAVASTATIN;
|
EID: 17744394863
PISSN: 00070920
EISSN: None
Source Type: Journal
DOI: 10.1054/bjoc.2000.1716 Document Type: Article |
Times cited : (354)
|
References (28)
|